Copyright ©The Author(s) 2018.
World J Gastrointest Oncol. May 15, 2018; 10(5): 115-123
Published online May 15, 2018. doi: 10.4251/wjgo.v10.i5.115
Table 1 Pharmacological modalities to reduce risk of gastric preneoplastic lesions and/or cancer
ReferencesDrugsStudy designNumber of subjectsResults
You et al[92], 2006Vitamin and garlic supplementRandomized controlled trial3365No protective effect
Leung et al[56], 2006RofecoxibRandomized controlled trial213Regression of IM: (a) antrum (24.5% vs 26.9% for placebo) (b) corpus (4.3% vs 2.2% for placebo)
Wong et al[57], 2012CelecoxibRandomized controlled trial1024OR of IM regression: (a) celecoxib alone (OR = 1.72; 95%CI: 1.07-2.76) (b) H. pylori eradication followed by celecoxib (OR = 1.48; 95%CI: 0.91-2.40)
Cheung et al[53], 2018AspirinPopulation-based retrospective cohort study63605PS-adjusted HR of GC: 0.30 (95%CI: 0.15-0.61)
Cheung et al[42], 2018Proton pump inhibitorsPopulation-based retrospective cohort study63397PS-adjusted HR of GC: 2.44 (95%CI: 1.42-4.20)